Drug intelligence / Profile preview

EXOMAGE

Development stage: Unknown
Lead developer: ExoCoBio
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

EXOMAGE is an exosome-based regenerative aesthetic biologic developed by the South Korean biotechnology company ExoCoBio. The product is formulated as a skin barrier ampoule serum containing over 108 million exosome particles stabilized via the proprietary ExoBRID technology, which utilizes a combination of β-glucan and methionine for protection. EXOMAGE is designed for topical application to facilitate the rapid restoration of damaged skin barriers, promote skin rejuvenation, and provide immune-modulatory effects. It is primarily indicated for use following aggressive cosmetic procedures to reduce wrinkles, improve skin elasticity, and deliver anti-inflammatory and anti-aging benefits.

Brand names: EXOMAGE

Beyond the preview

Go deeper on EXOMAGE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXOMAGE.

Explore the full profile